Composition principles of prescriptions for bronchial asthma in the randomized controlled clinical trials based on data mining technology
WANG Shengnan1 CHEN Yuanbin2,3 CHEN Ruifeng1 YANG Jianya1 XU Yinji3
1.The Second Clinical College, Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510405, China;
2.Zhou Zhongying Academic Experience Inheritance Studio, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Province, Guangzhou 510120, China; 3.Pneumology of Department, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Province, Guangzhou 510120, China
Abstract：Objective To analyze the prescription and herb rules of traditional Chinese medicines (TCMs) in the treatment of bronchial asthma in CNKI, Wanfang and CBM databases based on the Traditional Chinese Medicine inheritance support platform system. Methods The randomized controlled clinical trials of Chinese medicine prescriptions in the treatment of bronchial asthma in related databases were search and screened from inception of the databases through May, 2017, and the medication rules of TCMs for bronchial asthma were analyzed by using data mining technology. Results A total of 15 832 literatures were retrieved, and 1244 articles for the treatment of asthma with Chinese Medicine were included. A total of 510 prescriptions were about treating asthma, involving 309 kinds of herbs. Heat-asthma, cold-asthma, dual vacuity of the lung and kidney were most common syndromes, the clinical frequently used prescriptions were Xiaoqinglong Tang, Shegan-Mahuang Decoction and Dingchuan Decoction, getting 7 new prescriptions. Conclusion Composition principles of prescriptions and syndromes differentiation for bronchial asthma in the randomized controlled clinical trials is basically consistent with Internal Medicine of Traditional Chinese Medicine, the used frequently of prescriptions containing ephedra is higher in acute attack stage, Yuping-feng Powder is most used in stable phase, the new prescriptions suggest complex pathogenesis of asthma, and provide reference for treatment with asthma.
王胜楠1 陈远彬2，3 陈瑞凤1 杨建雅1 许银姬3. 应用数据挖掘技术分析支气管哮喘随机对照临床试验的方药规律[J]. 中国医药导报, 2018, 15(7): 107-110.
WANG Shengnan1 CHEN Yuanbin2,3 CHEN Ruifeng1 YANG Jianya1 XU Yinji3. Composition principles of prescriptions for bronchial asthma in the randomized controlled clinical trials based on data mining technology. 中国医药导报, 2018, 15(7): 107-110.
[1] 周仲瑛.中医内科学[M].北京：中国中医药出版社，2012.
[2] 唐仕欢，申丹，卢朋，等.中医传承辅助平台应用评述[J].中华中医药杂志，2015，30（2）：329-331.
[3] 赖世隆.中西医结合临床科研方法学[M].北京：科学出版社，2008.
[4] Lee MR. The history of Ephedra （ma-huang）[J]. J R Coll Physicians Edinb，2011，41（1）：78-84.
[5] Nagai T，Nakao M，Shimizu Y，et al. Proteomic Analysis of Anti-inflammatory Effects of a Kampo （Japanese Herbal） Medicine “Shoseiryuto （Xiao-Qing-Long-Tang）”on airway inflammation in a mouse model [J]. Evid Based Complementary Alternative Med，2011，2011（2）：604 196.
[6] Tanaka M，Inoue K，Kitamura Y，et al. In vitro action of sho-seiryu-to on allergen-exposed mononuclear cells [J]. Int J Immunopathol Pharmacol，2014，27（4）：607-610.
[7] 李星，蒋鹏娜，王雪慧，等.小青龙汤联合西药治疗成人哮喘随机对照试验的Meta分析[J].中华中医药杂志，2016， 31（9）：3502-3508.
[8] 刘鑫，邹中兰，梅全慧，等.射干麻黄汤对慢性哮喘大鼠缺氧诱导因子-1α、血管内皮生长因子表达及气道重塑的影响[J].中国实验方剂学杂志，2012，18（8）：190-195.
[9] Kao ST，Chang CH，Chen YS，et al. Effects of Ding-Chuan-Tang on bronchoconstriction and airway leucocyte infiltration in sensitized guinea pigs [J]. Immunopharmacol Immunotoxicol，2004，26（1）：113-124.
[10] 于鸿，计忠宇，赵辉，等.定喘汤对支气管哮喘大鼠气道重塑及嗜酸粒细胞的影响[J].中国中医急症，2011（9）：1437-1438.
[11] 元·朱丹溪.丹溪心法·哮喘十四[M].北京：人民卫生出版社，2005.
[12] 周玲.三拗汤治疗支气管哮喘的效应物质基础研究[D].南京：南京中医药大学.
[13] 清·尤在泾.金匮要略心典[M].北京：中国中医药出版社，2009.
[14] 王静珍，陶上乘，邢永春，等.紫苏与白苏药理作用的研究[J].中国中药杂志，1997，（1）：49-52，64.
[15] 明·秦昌遇.症因脉治[M].北京：中医古籍出版社，2000.
[16] 崔红生，武维屏，任传云，等.加减乌梅丸治疗激素依赖型哮喘20例临床疗效观察[J].中国中医基础医学杂志，2004（8）：49-50.
[17] 何清湖.新用乌梅丸治疗激素依赖型哮喘[J].中国中医药现代远程教育，2006，4（1）：38.
[18] 李建生，王至婉，余学庆，等.支气管哮喘证候诊断标准研究[J].中医学报，2015，30（6）：790-794.
2018, Vol. 15 
京公网安备 11010502046598号